Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 59, Issue 10, Pages 6605-6607Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01165-15
Keywords
-
Categories
Ask authors/readers for more resources
Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-beta-lactam beta-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 mu g/ml) from a patient with no prior treatment with ceftazidime-avibactam.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available